DAIICHI SANKYO CO LTD

Japan’s Daiichi Sankyo partners with China’s Innovent to launch FLT3‑inhibitor Vanflyta, speeding access for FLT3‑ITD AML patients and boosting regional oncology pipelines.

Explore AstraZeneca’s breakthrough Sone‑Ve ADC in CLDN18.2‑positive gastric cancer, its 2026 financial outlook, and strategic partnerships driving future growth.

Discover which pharma giants dominate the market by mastering patents, pipeline depth, and clinical proof—insights for investors seeking long‑term value.

EMA backs Enhertu + pertuzumab for HER2‑positive metastatic breast cancer, offering 85% ORR, 36‑month PFS and a manageable safety profile to reshape first‑line treatment.

DAIICHI Sankyo joins Japan’s Noetra Corp AI consortium to build a sovereign multimodal foundation model, boosting industrial automation, predictive maintenance, and regulatory compliance for robotics.

EMA approves AstraZeneca‑Daiichi Sankyo’s Enhertu and Datroway ADCs—pioneering tumor‑agnostic HER2 therapy and first‑line TNBC treatment—shaping European oncology, pricing, and reimbursement strategies.

Explore how Daiichi Sankyo’s €1 billion investment in Germany boosts its EU market‑access, tackles patent cliffs, and fuels biologics innovation.

Discover how Daiichi Sankyo’s partnership with AstraZeneca on ADC Datroway is reshaping high‑margin oncology markets, driving $1.2 B annual sales and patient‑centric pricing.

DS’s ADC push—Ifinatamab Deruxtecan for SCLC and Raludotag for ovarian cancer—sets a new growth path, backed by Merck and 2030 sales targets.

Regulatory wins for AstraZeneca and Daiichi Sankyo—Enhertu, Datroway and camizestrant—signal a surge in tumour‑agnostic, ADC‑based oncology therapies that promise broader market reach and stronger value‑based pay‑for‑performance models.